Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Avita Medical ( (RCEL) ) has shared an announcement.
On November 5, 2025, AVITA Medical agreed to a sixth amendment to its credit agreement with OrbiMed Advisors, adjusting the revenue covenant to $70 million for the quarter ending December 31, 2025. The amendment also waived a ‘going concern’ requirement for the third quarter, with AVITA adding $500,000 to the principal balance as consideration. The company’s Q3 2025 financial results showed a 13% decrease in commercial revenue compared to the previous year, attributed to reimbursement challenges. However, operating expenses decreased by 24%, and net loss improved. AVITA received CE Mark approval for RECELL GO® in Europe, expanding its international presence. The company is focusing on key U.S. centers and expects full-year revenue between $70 and $74 million, down from prior guidance.
The most recent analyst rating on (RCEL) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Avita Medical stock, see the RCEL Stock Forecast page.
Spark’s Take on RCEL Stock
According to Spark, TipRanks’ AI Analyst, RCEL is a Neutral.
Avita Medical’s overall stock score is primarily impacted by its financial instability, with negative equity and ongoing losses being major concerns. Technical indicators suggest weak momentum, and the valuation is unattractive due to a negative P/E ratio. While the earnings call and corporate events provide some positive outlook, they are insufficient to significantly improve the overall score.
To see Spark’s full report on RCEL stock, click here.
More about Avita Medical
AVITA Medical, Inc. is a leading therapeutic company in the acute wound care industry, focusing on delivering transformative solutions. The company is known for its RECELL technology, which is designed to treat burn and traumatic wounds. AVITA Medical targets an addressable market segment estimated at $1.3 billion, primarily focusing on approximately 200 key U.S. burn and trauma centers.
Average Trading Volume: 647,771
Technical Sentiment Signal: Sell
Current Market Cap: $96.36M
For detailed information about RCEL stock, go to TipRanks’ Stock Analysis page.